A new potent hFIX plasmid for hemophilia B gene therapy

Pharmaceutical Research

Volumn 21, Issue 7, 2004, Pages 1229-1232

  Lee, Jeoung Soo ^a   Lee, Minhyung ^b   Kim, Sung Wan ^a  

^a UNIVERSITY OF UTAH   (United States)

^b Inha University School of Medicine   (South Korea)

Author keywords

Factor IX; Hemophilia B; non viral gene therapy

Indexed keywords

APOLIPOPROTEIN E; PLASMID DNA; POLYETHYLENEIMINE; RECOMBINANT BLOOD CLOTTING FACTOR 9; RESTRICTION ENDONUCLEASE; TRYPSIN INHIBITOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA TRANSFECTION; DRUG POTENCY; ENHANCER REGION; ENZYME PURIFICATION; EXPRESSION VECTOR; GENE CASSETTE; GENE CONSTRUCT; GENE EXPRESSION; GENE ISOLATION; GENE THERAPY; HEMOPHILIA B; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECOMBINANT PLASMID; VIRAL GENE THERAPY;

ANIMALS; CELL LINE; DRUG CARRIERS; FACTOR IX; GENE THERAPY; HEMOPHILIA B; HUMANS; MICE; PLASMIDS; POLYETHYLENEIMINE; PROMOTER REGIONS (GENETICS); SIMIAN VIRUS 40; TRANSFECTION;

EID: 3242698023     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000033010.96920.33     Document Type: Article

References (15)

1. R. O. Snyder, C. Miao, L. Meuse, J. Tubb, B. A. Donahue, H-F Lin, D. W. Stafford, S. Patel, A. R. Thompson, T Nichols, M. S. Read, D. A. Bellinger, K. M. Brinkhous and M. A. Kay. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat. Med. 5:64-70 (1999).
2. L. Wang, T. C. Nichols, M. S. Read, D. A. Bellinger and I. M. Verma. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol. Ther. 1:154-158 (2000).
3. M. A. Kay, C. N. Landen, S. R. Rothenburg, L. A. Taylor, F. Leland, S. Wiehle, B. Fang, D. Bellinger, M. Finegold, A. R. Thompson, M. Read, K. M. Brinkhous, and S. L. C. Woo. In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc. Natl. Acad. Sci. U.S.A. 91:2353-2357 (1994).
4. L. Wang, K. Takabe, S. M. Bidlingmaier, C. R. III, and I. M. Verma. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc. Natl. Acad. Sci. U.S.A. 96:3906-3910 (1999).
5. M. Le, T. Okuyama, S.-R. Cai, S. C. Kennedy, W. M. Bowling, M. W. Flye, and K. P. Ponder. Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy. Blood 89:1254-1259 (1997).
6. W. P. Parks, D. W. Boucher, J. L. Melnick, L. H. Taber, and M. D. Yow. Seroepidemiological and ecological studies of the adenovirus-associated satellite viruses. Infect. Immun. 2:716-722 (1970).
7. M. V. Ragni, G. E. Tegtmeier, J. A. Levy, L. S. Kaminsky, J. H. Lewis, J. A. Spero, F. A. Bontempo, C. Handwerk-Leber, W. L. Bayer, and D. H. Zimmerman, et al. AIDS retroviral antibodies in hemophiliacs treated with factor VIII or factor IX concentrates, cryoprecipitates, or fresh frozen plasma prevalence, seroconversion rate, and clinical correlations. Blood 67:592-595 (1986).
8. J. Dhawan, L. C. Pan, G. K. Pavlath, M. A. Travis, A. M. Lanctot, and H. M. Blau. Systemic delivery of human growth hormone by injection of genetically engineered myoblast. Science 254:1509-1512 (1991).
9. K. J. Fisher, G-P. Gao, M. D. Weitzman, R. DeMatteo, J. F. Burda, and J. F. Wilson. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J. Virol. 70:520-532 (1996).
10. K. J. Fisher, K Jooss, J. Alston, Y. Yang, S. E. Haecker, K. A. High, R. Pathak, S. E. Raper and J. M. Wilson. Recombinant adeno-associated virus for muscle directed gene therapy. Nat. Med. 3:306-312 (1997).
11. L. M. Mir, M.F. Bureau, J. Gehl, R. Rangara, D. Rouy, J-M. Caillaud, P. Delaere, D. Branellec, B. Schwartz, and D. Scherman. High-efficiency gene transfer into skeletal muscle mediated by electric pulse. Proc. Natl. Acad. Sci. U.S.A. 96:4262-4267 (1999).
12. R. W. Herzog, J. D. Mount, V. R. Arruda, K. A. High, and C. D. Lothrop Jr. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol. Ther. 4:192-200 (2001).
13. R. W. Herzog, J. N. Hagstrom, S-H. Kung, S. J. Tai, J. M. Wilson, K. J. Fisher, and K A. High. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. U.S.A. 94:5804-5809 (1997).
14. S. N. Yao, and K. Kurachi. A simple treatment of serum for precise determination of recombinant factor IX in the culture media. Biotechniques 12:524-526 (1992).
15. V. R. Arruda, J. N. Hagstrom, J. Deitch, T. Heiman-Patterson, R. M. Camire, K. Chu, P. A. Fields, R. W. Herzog, L. B. Couto, P. J. Larson, and K. A. High. Posttranslational modifications of recombinant myotube-synthesized human factor IX. Blood 97:130-138 (2001).